Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas

Journal of Investigative Dermatology

Volumn 133, Issue 8, 2013, Pages 2041-2049

  Liu, Fang ^a,b   Cao, Juxiang ^a   Wu, Jinxiang ^a   Sullivan, Kayleigh ^a   Shen, James ^a   Ryu, Byungwoo ^a   Xu, Zhixiang ^c   Wei, Wenyi ^d   Cui, Rutao ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; FIBROBLAST GROWTH FACTOR 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR PAX3; TYRPHOSTIN; UNCLASSIFIED DRUG; VEMURAFENIB; WP 1066;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SENSITIVITY; FIBROBLAST; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; INDUCED RESISTANCE; KERATINOCYTE; MELANOMA; MELANOMA CELL; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION;

EID: 84880325633     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.32     Document Type: Article

References (64)

1. Abrahams A, Mowla S, Parker MI et al. (2008) UV-mediated regulation of the anti-senescence factor Tbx2. J Biol Chem 283:2223-30
2. Amin HM, McDonnell TJ, Ma Y et al. (2004) Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23:5426-34 (Pubitemid 39044053)
3. Barr FG, Fitzgerald JC, Ginsberg JP et al. (1999) Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res 59:5443-8 (Pubitemid 29526453)
4. Basse B, Joseph WR, Marshall ES et al. (2010) Analysis of radiation-induced changes to human melanoma cultures using a mathematical model. Cell Prolif 43:139-46
5. Berking C, Takemoto R, Satyamoorthy K et al. (2001) Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol 158:943-53 (Pubitemid 32221786)
6. Blake JA, Ziman MR (2005) Pax3 transcripts in melanoblast development. Dev Growth Differ 47:627-35 (Pubitemid 43151678)
7. Bollag G, Hirth P, Tsai J et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-9
8. Brose MS, Volpe P, Feldman M et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000 (Pubitemid 35424092)
9. Carreira S, Dexter TJ, Yavuzer U et al. (1998) Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter. Mol Cell Biol 18:5099-108 (Pubitemid 28388093)
10. Catlett-Falcone R, Landowski TH, Oshiro MM et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-15 (Pubitemid 29077388)
11. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
12. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20:2149-82
13. Dai B, Meng J, Peyton M et al. (2011) STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71:3658-68
14. Dankort D, Curley DP, Cartlidge RA et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-52
15. Darnell JE (2005) Validating Stat3 in cancer therapy. Nat Med 11:595-6
16. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54 (Pubitemid 34716871)
17. Dong L, Li Y, Cao J et al. (2012) FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription. Cell Death Differ 19:616-22
18. Dunham WR, Klein SB, Rhodes LM et al. (1996) Oleic acid and linoleic acid are the major determinants of changes in keratinocyte plasma membrane viscosity. J Invest Dermatol 107:332-5 (Pubitemid 26284339)
19. Epstein DJ, Vogan KJ, Trasler DG et al. (1993) A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant. Proc Natl Acad Sci USA 90:532-6 (Pubitemid 23028897)
20. Fecher LA, Cummings SD, Keefe MJ et al. (2007) Toward a molecular classification of melanoma. J Clin Oncol 25:1606-20 (Pubitemid 46733089)
21. Ferrajoli A, Faderl S, Van Q et al. (2007) WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67:11291-9 (Pubitemid 350248555)
22. Flaherty KT, McArthur G (2010) BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116:4902-13
23. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19
24. Garraway LA, Widlund HR, Rubin MA et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22 (Pubitemid 40966196)
25. Ginsberg M, Czeko E, Muller P et al. (2007) Amino acid residues required for physical and cooperative transcriptional interaction of STAT3 and AP-1 proteins c-Jun and c-Fos. Mol Cell Biol 27:6300-8 (Pubitemid 47435738)
26. Halaban R, Langdon R, Birchall N et al. (1988) Paracrine stimulation of melanocytes by keratinocytes through basic fibroblast growth factor. Ann N Y Acad Sci 548:180-90
27. Hatiboglu MA, Kong LY, Wei J et al. (2012) The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 131:8-17
28. Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-23
29. Horikawa T, Norris DA, Zekman T et al. (1996) Effective elimination of fibroblasts in cultures of melanocytes by lowering calcium concentration in TPA depleted medium following geneticin treatment. Pigment Cell Res 9:58-62 (Pubitemid 126478568)
30. Hussain SF, Kong LY, Jordan J et al. (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67:9630-6 (Pubitemid 47621208)
31. Imokawa G, Yada Y, Miyagishi M (1992) Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 267:24675-80
32. Jaye M, Schlessinger J, Dionne CA (1992) Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1135:185-99
33. Johannessen CM, Boehm JS, Kim SY et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-72
34. Joseph EW, Pratilas CA, Poulikakos PI et al. (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAFselective manner. Proc Natl Acad Sci USA 107:14903-8
35. Kong LY, Abou-Ghazal MK, Wei J et al. (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14:5759-68
36. Kong LY, Wei J, Sharma AK et al. (2009) A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58:1023-32
37. Kortylewski M, Jove R, Yu H (2005) Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24:315-27 (Pubitemid 40922802)
38. Krasilnikov M, Ivanov VN, Dong J et al. (2003) ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22:4092-101 (Pubitemid 36819649)
39. Lee I, Fox PS, Ferguson SD et al. (2012) The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget 3:336-44
40. Levy DE, Inghirami G (2006) STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 103:10151-2 (Pubitemid 44051135)
41. Moase CE, Trasler DG (1992) Splotch locus mouse mutants: models for neural tube defects and Waardenburg syndrome type I in humans. J Med Genet 29:145-51
42. Nazarian R, Shi H, Wang Q et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7
43. Paraiso KH, Fedorenko IV, Cantini LP et al. (2010) Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102:1724-30
44. Plummer RS, Shea CR, Nelson M et al. (2008) PAX3 expression in primary melanomas and nevi. Mod Pathol 21:525-30 (Pubitemid 351589648)
45. Pollock PM, Meltzer PS (2002) A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2:5-7 (Pubitemid 41043982)
46. Poulikakos PI, Rosen N (2011) Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19:11-5
47. Read AP, Newton VE (1997) Waardenburg syndrome. J Med Genet 34:656-65 (Pubitemid 27356884)
48. Rodriguez M, Aladowicz E, Lanfrancone L et al. (2008) Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res 68:7872-81
49. Ruggiero RA, Bruzzo J, Chiarella P et al. (2012) Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control. Cancer Res 72:1043-50
50. Scholl FA, Kamarashev J, Murmann OV et al. (2001) PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 61:823-6 (Pubitemid 32174385)
51. Shi H, Kong X, Ribas A et al. (2011) Combinatorial treatments that overcome PDGFR{beta}-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71:5067-74
52. Smalley KS, Herlyn M (2005) Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann NY Acad Sci 1059:16-25 (Pubitemid 43211606)
53. Steingrimsson E, Copeland NG, Jenkins NA (2005) Melanocyte stem cell maintenance and hair graying. Cell 121:9-12
54. Straussman R, Morikawa T, Shee K et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4
55. Tassabehji M, Newton VE, Leverton K et al. (1994) PAX3 gene structure and mutations: close analogies between Waardenburg syndrome and the Splotch mouse. Hum Mol Genet 3:1069-74 (Pubitemid 24211949)
56. Tassabehji M, Read AP, Newton VE et al. (1992) Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. Nature 355:635-6
57. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012
58. Vachtenheim J, Novotna H (1999) Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. Cell Mol Biol 45: 1075-82
59. Verstovsek S, Manshouri T, Quintas-Cardama A et al. (2008) WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14:788-96 (Pubitemid 351231161)
60. Villanueva J, Vultur A, Lee JT et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95
61. Wagle N, Emery C, Berger MF et al. (2011) Dissecting therapeutic resistance to raf inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-96
62. Wang W, Edington HD, Rao UN et al. (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by highdose IFNalpha2b. Clin Cancer Res 13:1523-31 (Pubitemid 46450444)
63. Yang G, Li Y, Nishimura EK et al. (2008) Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell 32:554-63
64. Zushi S, Shinomura Y, Kiyohara T et al. (1998) STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 78:326-30 (Pubitemid 28445370)